Used primarily in pharmaceutical research and development, this compound functions as a PROTAC (Proteolysis Targeting Chimera) linker or intermediate. It enables targeted protein degradation by bridging an E3 ubiquitin ligase ligand to a protein-binding moiety, facilitating the ubiquitination and subsequent degradation of disease-related proteins. Its structure supports enhanced selectivity and cellular permeability, making it valuable in oncology and inflammatory disease research. Commonly employed in the design of degraders for transcription factors and kinases, it contributes to the development of therapies with improved efficacy and reduced off-target effects.